Whitehawk Therapeutics (NASDAQ:WHWK) Raised to Hold at Zacks Research

Key Points

• Whitehawk Therapeutics has been upgraded from a "strong sell" rating to a "hold" rating by Zacks Research, while analysts from Weiss Ratings maintain a "sell (e+)" rating.
• As of Tuesday, shares of Whitehawk Therapeutics traded at $2.13, with a 52-week range of $1.39 to $3.81.
• The company reported an earnings per share (EPS) of ($0.76), significantly missing analysts' expectations of $0.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Whitehawk Therapeutics in a research report on Wednesday. Wall Street Zen lowered Whitehawk Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce".

Whitehawk Therapeutics Trading Down 4.1%

Shares of NASDAQ WHWK opened at $2.13 on Tuesday. The firm has a 50 day moving average price of $1.83. The stock has a market capitalization of $100.38 million, a price-to-earnings ratio of -35.50 and a beta of 0.58. Whitehawk Therapeutics has a 52 week low of $1.39 and a 52 week high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 75.99%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.